SIGA Technologies Inc. Common Stock (SIGA)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings and a margin of safety. SIGA is a tiny $221.3M market-cap commercial-stage pharmaceutical company whose lead product, TPOXX, treats smallpox for the U.S. health security market. That niche can have high barriers, but it is not a stable consumer franchise. Filed results are wildly lumpy: fiscal Q2 2026, the quarter ended 2026-06-30, had revenue of $41.0M and net income of $12.5M, or diluted EPS of $0.17. Yet fiscal Q1 2026, the quarter ended 2026-03-31, had revenue of $6.2M and a net loss of $3.5M, or diluted EPS of -$0.05. Annual figures are shrinking: FY2023 revenue was $139.9M, net income $68.1M, EPS $0.95; FY2024 revenue was $138.7M, net income $59.2M, EPS $0.82; FY2025 revenue was $94.6M, net income $23.3M, EPS $0.32. FairStock classifies it as a slow grower that is shrinking: profit -16.2% a year over five years and revenue -5.4%. The balance sheet looks safe—D/E is 0.00 and Altman Z-Score is 13.69—and Piotroski is 7/9. But FairStock's ROE is -1.49%, ROCE is -3.39%, trailing free cash flow is -$20.5M, and FCF yield is -9.3%. At the $3.08 close on 2026-10-13, FairStock's P/B is 1.34 and P/E is -77.00. I see a narrow, contract-dependent business with erratic economics. Without evidence of renewed government orders, the shares look more speculative than cheap.

In plain English: SIGA Technologies makes TPOXX, an antiviral medicine for smallpox, mainly for U.S. government health security programs. The business is uneven: it has profitable quarters but also losses, and annual sales and profits have fallen from earlier peaks. At $3.08 a share and a $221.3 million market value, the price looks mixed rather than clearly cheap, because the company has no debt but is currently burning cash and earnings are hard to predict.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer